Xeris Biopharma Stock Soars to Multiyear High as Recorlev Sales Nearly Double and 2030 Target Tops $1 Billion
Xeris Biopharma (XERS) shares rose 29% to $13.46 after reporting a 44% revenue increase to $107M, with Recorlev sales up 93% to $71.5M. The company raised its 2026 revenue forecast to $395M-$405M and targets $1B by 2030. Net income increased to $11.3M, and adjusted EBITDA reached $30.8M.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift triggered a near‑30% price jump, suggesting further upside if growth continues.
Market read
Strong earnings and guidance raise make XERS a high‑impact trade idea for biotech investors today.
What to watch
Higher SG&A spending and reliance on a single product (Recorlev) could pressure margins later.
Background
Xeris Biopharma reported its latest quarterly results, showing strong growth in its flagship drug Recorlev and raising long‑term revenue targets.
Ticker impact
Quarterly revenue rose 44% to $107M, net income jumped to $11.3M and guidance was raised, prompting a 29% stock surge.
upward pressure as the market prices in the earnings beat and higher 2026/2030 revenue outlook.
Revenue and profit beat expectations, guidance lift, and a near‑term price jump indicate continued buying interest.
Market effects
Boosts sentiment for rare‑disease and endocrine biotech peers.
Positive for US biotech sector.
Limited to biotech investors; no broader macro effect.
Counterpoint
If the revenue surge is not sustainable, the stock may be overbought after a rapid rally.
Key entities
- companyXeris Biopharma Holdings Inc.
Endocrine and rare‑disease drugmaker listed on Nasdaq (XERS).
- productRecorlev
Treatment for endogenous Cushing's syndrome driving most of the revenue growth.
